Sarepta Therapeutics reported $914.74M in Stock for its fiscal quarter ending in December of 2025.





Stock Change Date
Acadia Pharmaceuticals USD 34.67M 5.57M Dec/2025
Agios Pharmaceuticals USD 32.92M 886K Dec/2025
Alnylam Pharmaceuticals USD 82.72M 7.34M Dec/2025
Amgen USD 6.22B 121M Dec/2025
BioCryst Pharmaceuticals USD 5.4M 166K Dec/2025
Biogen USD 2.17B 41.3M Dec/2025
BioMarin Pharmaceutical USD 1.3B 83.29M Dec/2025
Daiichi Sankyo JPY 608.55B 93.64B Sep/2025
Eli Lilly USD 13.74B 1.56B Dec/2025
Esperion Therapeutics USD 108.54M 5.93M Sep/2025
Gilead Sciences USD 1.78B 40M Sep/2025
Incyte USD 101.06M 17.61M Dec/2025
Insmed USD 132.07M 11.1M Dec/2025
Ionis Pharmaceuticals USD 10.47M 1.99M Sep/2025
Moderna USD 332M 92M Sep/2025
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 69M 300K Dec/2025
Novavax USD 11.54M 1.97M Dec/2025
Pfizer USD 11.47B 201M Sep/2025
PTC Therapeutics USD 79.65M 26.96M Dec/2025
Regeneron Pharmaceuticals USD 3.2B 53.6M Dec/2025
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 22.69B 1.81B Dec/2025
Sarepta Therapeutics USD 914.74M 162.42M Dec/2025
Ultragenyx Pharmaceutical USD 52.2M 5.7M Sep/2025
Vertex Pharmaceuticals USD 1.69B 60M Dec/2025